This is a working overview of prothymosin alpha, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-02 and is reviewed periodically as new material appears.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Birch bark tar was more frequently discovered in archaeological contexts dating from the Neolithic to the Iron Age. For example, birch bark tar was identified to serve as an adhesive to repair and decorate/paint ceramic vessels, as a sealing/waterproofing agent. A well-known example of birch bark tar hafting during the copper age is Ötzi’s hafted arrow points and copper axe. Multiple discoveries show that birch bark tar was also used to assemble metal artefacts, such as pendants and other ornaments, on both a functional and decorative level. During the Roman Era, birch bark tar is mostly replaced by wood tar, but birch bark tar is still used, for example, to decorate hinges and other bone objects.
The U.S. Food and Drug Administration noted in 2007 that fruit and vegetable-related outbreaks of food poisoning are on the rise and had struck in spinach, tomatoes, lettuce and cantaloupes. The agency urged fruit and vegetable processors to adopt food safety plans similar to those in the meat industry. An outbreak of Salmonella Saintpaul in 2008 was characterized by the US Center for Disease Control as the largest foodborne outbreak in a decade. Some 1304 infected persons were identified in 43 states, at least 252 were hospitalized and two deaths were possibly linked to the outbreak. CDC noted that the trace back of fresh produce, such as tomatoes, through the supply chain could be very difficult and labor-intensive. Ironically, the carrier item was ultimately determined to be jalapeño peppers, not tomatoes.
On October 21, 2025, Gallrein announced his candidacy for the United States House of Representatives for Kentucky's 4th congressional district, challenging seven-term incumbent Thomas Massie in the Republican primary. Massie had held the seat since 2012, and was considered to be popular within the district; in 2024 he had won the Republican primary with 76% of the vote, and the general election with 99.6% of the vote. President Donald Trump endorsed Gallrein on October 17, 2025. The primary was the most expensive congressional primary in U.S. history, costing over $25 million. Gallrein won the Republican nomination on May 19, 2026, 54.9%–45.1%, winning 19 of the 21 counties that voted. After the race against Massie was called in Gallrein's favor, Gallrein said: "It was a David versus Goliath. I was the underdog." Gallrein will face Democrat Melissa Strange in the general election on November 3, 2026.
=== Stages of healing === The graft is carefully spread on the bare area to be covered. It is held in place by a few small stitches or surgical staples. The healing process for skin grafts typically occurs in three stages: plasmatic imbibition, capillary inosculation, and neovascularization. During the first 24 hours, the graft is initially nourished by a process called plasmatic imbibition in which the graft "drinks plasma" (i.e., absorbs nutrients from the underlying recipient bed). Between 2 and 3 days, new blood vessels begin growing from the recipient area into the transplanted skin in a process called capillary inosculation. Between 4 and 7 days, neovascularization occurs in which new blood vessels form between the graft and the recipient tissues.
==== LSm12 ==== Using entirely different affinity techniques, other workers unexpectedly identified a member of an RNA-binding protein LSm family (LSm12) as an NAADP-dependent accessory protein for TPCs. Composed of two domains (an N-terminus LSm domain and a C-terminus anticodon-binding [AD] domain), LSm12 mediates NAADP activation of TPCs via its LSm domain. This domain binds NAADP with appropriate nanomolar affinity and selectivity over NADP, and appears to be needed for activation of either TPC1 or TPC2 (contrasting with the isoform-selectivity of JPT2). Other LSm family members (5 and 11) were not required. The fact that two entirely different proteins potentially converge on the activation of TPCs raises future questions of whether both NAADP-binding proteins are part of a common complex or pathway.
Sources: en.wikipedia.org
"Impact of elevated CO2 on shellfish calcification". Geophysical Research Letters. 34 (7): L07603. Bibcode:2007GeoRL..34.7603G. doi:10.1029/2006GL028554. hdl:20.500.11755/a8941c6a-6d0b-43d5-ba0d-157a7aa05668. Gattuso, J.-P.; Hansson, L.; "Ocean acidification" (Oxford University Press) Kroeker, K.; Kordas, R.; Crim, R.; Hendriks, I.; Ramajo, L.; Singh, G.; Duarte, C.; Gattuso, J.-P. (2013). "Impacts of ocean acidification on marine organisms: quantifying sensitivities and interaction with warming". Global Change Biology. 19 (6): 1884–1896. Bibcode:2013GCBio..19.1884K. doi:10.1111/gcb.12179. PMC 3664023. PMID 23505245. Gattuso, J.-P.; Magnan, A.; Billé, R.; Cheung, W.W.L.; Howes, E.L.; Joos, F.; Allemand, D.; Bopp, L.; Cooley, S.; Eakin, C.M.; Hoegh-Guldberg, O.; Kelly, R.P.; Pörtner, H.; Rogers, A.D.; Baxte, J.M.; Laffoley, D.; Osborn, D.; Rankovic, A.; Rochette, J.; Sumaila, U. R.; Treyer, S.; Turley, C. (2015). "Contrasting futures for ocean and society from different anthropogenic CO2 emissions scenarios" (PDF). Science. 349 (6243) aac4722. doi:10.1126/science.aac4722. PMID 26138982. S2CID 206639157. Magnan, A.K.; Colombier, M.; Billé, R.; Hoegh-Guldberg, O.; Joos, F.; Pörtner, H.-O; Waisman, H.; Spencer, T.; Gattuso, J.-P. (2016). "Implications of the Paris Agreement for the ocean". Nature Climate Change. 6 (8): 732–735. Bibcode:2016NatCC...6..732M. doi:10.1038/nclimate3038. Gattuso, J.-P.; Williamson, P.; Duarte, C.; Magnan, A.K. (2021). "The potential for ocean-based climate action: negative emissions technologies and beyond". Frontiers in Climate. 2 575716.
Herbivorous dinosaurs exhibited convergent evolution towards one of two feeding strategies, one strategy resembling mammalian herbivores (emphasizing chewing-specialized morphology, with the skull acquiring and processing food) and another strategy analogous to herbivory in birds and reptiles (emphasizing a specialized gut as in the avian gizzard, with the skull used only for acquiring rather than processing food).
== Further reading == Buckley RH (2004). "Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution". Annu Rev Immunol. 22: 625–55. doi:10.1146/annurev.immunol.22.012703.104614. PMID 15032591. Chinen J, Puck JM (2004). "Successes and risks of gene therapy in primary immunodeficiencies". J Allergy Clin Immunol. 113 (4): 595–603, quiz 604. doi:10.1016/j.jaci.2004.01.765. PMID 15100660. Church AC (2002). "X-linked severe combined immunodeficiency". Hosp Med. 63 (11): 676–80. doi:10.12968/hosp.2002.63.11.1914. PMID 12474613. Gennery AR, Cant AJ (2001). "Diagnosis of severe combined immunodeficiency". J Clin Pathol. 54 (3): 191–5. doi:10.1136/jcp.54.3.191. PMC 1731376. PMID 11253129.
== Therapeutic relevance == Fundamental discoveries uncovering the biology of ferroptosis and translational studies showing the disease relevance of ferroptosis have motivated efforts to develop therapeutics that modulate ferroptosis. For example, Kojin Therapeutics and PTC Therapeutics are exploring ferroptosis modulation for treatment of cancer and Friedrich's ataxia. Ferroptosis has been implicated in a range of different diseases including cancer, ischemia/reperfusion injury (IRI), inflammation, neurodegeneration, and kidney injury.
Sources: en.wikipedia.org
== Chemoenzymatic strategies == There is no general biochemical solution for macrocyclization of a peptide chain. Isolated tyrocidine (Tyc) TE domains can be used to cyclize chemically derived peptidyl-thioester substrates, providing a powerful route to new cyclic compounds. In order for this macrocyclization to occur, the peptide chain must be activated at its C-terminus with an N-acetylcysteamine (SNAC) leaving group. An alanine scan through the 10 positions of tyrocidine shows that only the D-Phe and L-Orn are required for sufficient cyclization.
The company also sponsored a complaint to the FDA, expressing concern that buprenorphine/naloxone sublingual tablets (the very product they formerly produced) were unsafe, requesting that applications for regulatory approval of generic products by other pharmaceutical companies (their competitors) be rejected by the US Food and Drug Administration.
=== Economics === Pembrolizumab was priced at US$150,000 per year when it launched in 2014. It was added to the Cancer Drugs Fund list of NHS England in November 2022 after a deal with manufacturer Merck Sharp and Dohme, the details of which remain confidential. Keytruda was the world's top-selling drug in 2024, with $29.5 billion in sales.
This demonstration was primarily set aboard a space station overtaken with genetically mutated monsters; the main character was Carlos Cuello, a "cult deprogrammer"—a person charged with rescuing someone from a cult, and mentally and psychologically readjusting that person to a normal life. This story would have been more political in nature, with the character hired by a Senator. The team collectively agreed that this direction was not what they had set out to make, and were having trouble finding a publisher, as immersive sims did not sell well. They considered ending development, but as news about their efforts to create a spiritual successor to System Shock 2 began to appear in gaming magazines and websites, the team opted to continue development, performing a full revamp. By 2004, 2K Games, a subsidiary of Take-Two Interactive, offered to publish the game primarily based on the drone/protector/harvester concept. By this point, the setting had shifted to an abandoned World War II-era Nazi laboratory that had been recently unearthed by 21st-century scientists. Over the decades, the genetic experiments within the labs had developed into the drone/protector/harvester ecosystem. This version included many of the gameplay elements that would remain in the final BioShock, themselves influenced by concepts from System Shock 2. These elements included the use of plasmids and weapon upgrades, or using stealth to evade enemies. When Irrational was acquired by 2K in 2006, the publisher boosted the previously-modest budget.
Burn scar contracture is the tightening of the skin after a second or third degree burn. When skin is burned, the surrounding skin begins to pull together, resulting in a contracture. It needs to be treated as soon as possible because the scar can result in restriction of movement around the injured area. This is mediated by myofibroblasts.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.